Discussion
This study demonstrates that asymptomatic HIV positive patients are able to mount adequate antibody response to influenza vaccine. Seventy-three percent of HIV positive patients were able to mount a four-fold or more antibody response to at least one of the four influenza antigens, and 50% achieve protec-tive antibody response to all vaccinated strains.
When compared with immunocompetent controls, HIV positive patients seem to mount a lower antibody response after vaccination. However, the difference was not statistically significant in all but one strain. We were unable to detect even a trend towards higher antibody response in patients with good CD4 count compared with those with low CD4 count. This is in contrast to the study by Kroon et 12 In the United States, up to a third of HIV infected adolescents and adults receive influenza vaccination." This study, together with others, have shown that if influenza immunisation is considered appropriate is a particular individual, adequate antibody response can be expected in asymptomatic patients, especially if the CD4 lymphocyte count is > 100 x 106/ml.9
Our study confirms the safety of the influenza vaccine. We were unable to demonstrate any deleterious effect of the vaccine on the course of HIV infection as evidenced by our observation on CD4 lymphocyte count. '4 Three months after immunisation, there was no change in the mean CD4 lymphocyte count. A median of 12 months later, the rate of CD4 lymphocyte decline was not different from that prior to immunisation. This confirms findings of other studies9 '0 which showed no unexpected change in CD4 lymphocyte count after influenza immunisation.
